Kovack Advisors Inc. Sells 2,644 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Kovack Advisors Inc. trimmed its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 1.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 146,158 shares of the company’s stock after selling 2,644 shares during the period. Kovack Advisors Inc. owned 0.27% of Zevra Therapeutics worth $1,219,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZVRA. International Assets Investment Management LLC increased its stake in shares of Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after purchasing an additional 5,940 shares during the last quarter. XTX Topco Ltd bought a new position in Zevra Therapeutics during the third quarter worth about $94,000. China Universal Asset Management Co. Ltd. acquired a new position in Zevra Therapeutics during the fourth quarter worth approximately $94,000. Intech Investment Management LLC bought a new stake in Zevra Therapeutics in the third quarter valued at approximately $95,000. Finally, Virtu Financial LLC acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at approximately $127,000. 35.03% of the stock is owned by institutional investors.

Insider Transactions at Zevra Therapeutics

In related news, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the sale, the chief financial officer now owns 51,361 shares of the company’s stock, valued at $403,697.46. This represents a 17.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Joshua Schafer sold 10,500 shares of Zevra Therapeutics stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $82,530.00. Following the completion of the transaction, the executive vice president now directly owns 29,486 shares of the company’s stock, valued at $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is currently owned by company insiders.

Zevra Therapeutics Price Performance

NASDAQ:ZVRA opened at $7.79 on Friday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The firm has a market cap of $415.80 million, a price-to-earnings ratio of -3.95 and a beta of 2.00. Zevra Therapeutics, Inc. has a 52 week low of $4.20 and a 52 week high of $9.76. The firm’s 50-day simple moving average is $8.07 and its 200 day simple moving average is $8.10.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Guggenheim set a $21.00 target price on Zevra Therapeutics and gave the stock a “buy” rating in a report on Tuesday, February 4th. Canaccord Genuity Group decreased their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Cantor Fitzgerald upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $21.71.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.